Kyle Malady Biography and Net Worth

Director of DexCom

Kyle Malady joined the Dexcom Board of Directors in 2020. Mr. Malady currently serves as Executive Vice President and Chief Executive Officer of Verizon Business. He leads the team responsible for delivering the next generation of technology-driven innovation to customers around the world, serving 99% of Fortune 500 companies in more than 120 countries.

Mr. Malady is a telecommunications industry expert with extensive experience in developing and implementing networks and applications for both the public and private sectors. He is a leader in the development of global 5G-related infrastructure.

Mr. Malady previously served as Executive Vice President and President of Verizon’s Global Networks and Technology team, responsible for the network and technology behind Verizon’s mobility, broadband and private network services.

In addition to his experience at Verizon, Mr. Malady manages Caelens Fund, a charity that raises money to provide free cardiac surgeries for children in developing countries. He also serves as Chairman of CTIA, the wireless industry association, and is a member of the National Security Telecommunications Advisory Committee (NSTAC), which advises the U.S. Government on critical national security and emergency preparedness challenges.

Mr. Malady holds an MBA in Finance from the NYU Stern School of Business and a Bachelor of Science in Mechanical Engineering from the University of Bridgeport.

What is Kyle Malady's net worth?: The estimated net worth of Kyle Malady is at least $1.48 million as of September 5th, 2025. Malady owns 22,667 shares of DexCom stock worth more than $1,479,022 as of December 4th. This net worth approximation does not reflect any other assets that Malady may own. Learn More about Kyle Malady's net worth.
How do I contact Kyle Malady?: The corporate mailing address for Malady and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Kyle Malady's contact information.
Has Kyle Malady been buying or selling shares of DexCom?: Kyle Malady has not been actively trading shares of DexCom over the course of the past ninety days. Most recently, Kyle Malady sold 667 shares of the business's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a transaction totalling $53,933.62. Following the completion of the sale, the director now directly owns 22,667 shares of the company's stock, valued at $1,832,853.62. Learn More on Kyle Malady's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Kyle Malady (Director), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, DexCom insiders bought shares 1 times. They purchased a total of 18,200 shares worth more than $1,001,728.00. During the last twelve months, insiders at the medical device company sold shares 23 times. They sold a total of 146,914 shares worth more than $11,338,819.79. The most recent insider tranaction occured on November, 14th when Director Richard Alexander Collins sold 2,906 shares worth more than $171,599.30. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 11/14/2025.

Kyle Malady Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/5/2025	Sell	667	$80.86	$53,933.62	22,667

Kyle Malady Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $65.25

$64.09

$65.34

50 Day Range

MA: $64.00

$54.84

$71.06

2 Week Range

Now: $65.25

$54.11

$93.25

Volume

3,482,117 shs

Average Volume

5,982,684 shs

Market Capitalization

$25.45 billion

P/E Ratio

36.25

Dividend Yield

N/A

Beta

1.51